Prospective phase I study of nivolumab to promote graft-versus-tumour in relapsed or refractory haematological malignancy post allogeneic haematopoietic stem cell transplantation. (PubMed, Br J Haematol) - Oct 17, 2026 - "These findings confirm that nivolumab can promote GVT post-alloHSCT, particularly in lymphoid disorders. Baseline immunophenotype (effector memory T cells, Human Leukocyte Antigen - DR isotype [HLA-DR]) and gene expression (granzyme A [GZMA], granzyme B [GZMB], perforin [PRF1]) can be used as biomarkers to help identify patients most likely to benefit from salvage checkpoint inhibition."
IO biomarker • Journal • P1 data • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Oncology • Pneumonia • Transplantation • GZMA • GZMB • PRF1
|
|
David Ritchie; Eric Wong; Jessica Klass; Joanne E Davis; Mandy Ludford-Menting; Rachel Koldej; Sara K Dohrmann; Trung Q Ngo
|